Xowna (LSTA16) / Lisata Therap - LARVOL DELTA

FREEDOM: A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction (clinicaltrials.gov) - P2 | N=34 | Terminated | Sponsor: Lisata Therapeutics, Inc. | N=105 ➔ 34 | Trial completion date: Jun 2023 ➔ Sep 2022 | Active, not recruiting ➔ Terminated; Sponsor decision

Enrollment change • Trial completion date • Trial termination • Cardiovascular • Coronary Artery Disease

FREEDOM: A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction (clinicaltrials.gov) - P2 | N=105 | Active, not recruiting | Sponsor: Caladrius Biosciences, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2022 ➔ Jun 2023 | Trial primary completion date: Apr 2022 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction. (PubMed, Circ Cardiovasc Interv) - P2 | "In this pilot clinical trial of microvascular angina, patients with ischemia and nonobstructive coronary artery disease receiving intracoronary infusion of CD34+ cell therapy had higher coronary flow reserve, less severe angina, and better quality of life at 6 months. The current study supports a potential therapeutic role for CD34+ cells in patients with microvascular angina."

Journal • Cardiovascular • Coronary Artery Disease • CD34

FREEDOM: A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction (clinicaltrials.gov) - P2; N=105; Recruiting; Sponsor: Caladrius Biosciences, Inc.

Clinical • New P2 trial • Cardiovascular • Coronary Artery Disease

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease (clinicaltrials.gov) - P2; N=20; Completed; Sponsor: Caladrius Biosciences, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Cardiovascular • Coronary Artery Disease

[VIRTUAL] Autologous CD34 Cell Therapy for Treatment of Coronary Microvascular Dysfunction in Patients With Angina and Non-Obstructive Coronary Arteries (SCAI 2020) - P2 | " We conducted a 2-center NHLBI-sponsored (R44HL135889) trial of autologous CD34+ cell therapy (CLBS16-P01)(NCT03508609) in 20 NOCAD pts with persistent angina and invasive coronary flow reserve (CFR) 2.5... CD34+ cell therapy appears to be a promising therapy for CMD patients with angina and NOCAD. A prospective randomized clinical trial is being planned. ."

Clinical • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Gene Therapies • Ischemic stroke • Reperfusion Injury • CD34 • CSF3